Wrapping up an inspiring #SIBCS2025 in Shanghai. So many brilliant minds working to transform breast cancer care. Thanks to everyone who stopped by booth #29 to chat about publishing with Sage Journals! #Oncology #BreastCancer #MedicalJournals

Kicking off #SIBCS2025 in Shanghai! Proud to represent Sage Publishing as Editor of Therapeutic Advances in Medical Oncology and Co-Editor of Clinical Medicine Insights: Oncology + Rare Tumors. Come say hi at booth #29! 🧬📚 #BreastCancer #Oncology #MedicalResearch

ADCs are transforming breast cancer care, but toxicity management remains key to patient outcomes. Read the full review 👉 buff.ly/Fp2c5JI #BreastCancer #Oncology #ADCs #CancerResearch

How poor is the prognosis for dialysis-dependent #MultipleMyeloma? This multicenter study confirms it's severe, but also identifies a path to hope. Achieving dialysis independence TRIPLES median overall survival. Key factors: VGPR, daratumumab, deep early light chain response.

📢 Real-world data from China on T-DXd in HER2+ and HER2-low advanced breast cancer is here! 🧬 PFS ~10 months 📈 ORR: 62.5% (HER2+) | 37.9% (HER2-low) ✅ Manageable safety profile T-DXd shows promise across HER2 expression levels. buff.ly/jrOE20b #BreastCancer #HER2 #Oncology #RealWorldEvidence #TDXd

🧠 SCLC remains one of the most aggressive cancers. This new review explores: 🔹 ICIs 🔹 Novel agents like lurbinectedin 🔹 Anti-DLL3 therapies 🔹 Molecular profiling for personalized care buff.ly/Mmx2f1V Hope is on the horizon for ES-SCLC. #LungCancer #SCLC #Oncology #CancerResearch #Immunotherapy

🚨 A multicenter study compares mFOLFOX-6 vs. mDCF in metastatic gastric & GEJ cancer. buff.ly/1NsLmel 🔍 Similar efficacy 📉 Lower toxicity with mFOLFOX-6 📊 493 patients across 25 hospitals Is doublet chemo the new standard? #GastricCancer #Oncology #GIcancer #Chemotherapy #CancerResearch

📢 Call for Papers! Submit to our special issue: “Geriatric Oncology: Advancing Cancer Care in an Aging World” 🗓️ Join the conversation on cancer care for older adults. buff.ly/ASkDwOt #GeriatricOncology #CancerResearch #Oncology #CallForPapers #MedicalPublishing

This review outlines current therapies and future directions for KRAS G12C-mutant NSCLC • Targeted inhibitors: sotorasib, adagrasib • Immunotherapy combos: checkpoint inhibitors + KRAS blockade • Dual ICI strategies under exploration Read more: buff.ly/KdmExKt #CancerResearch #NSCLC #KRASG12C

TAMO Article examines ctDNA in guiding chemo for stage II colon cancer. Findings? ctDNA combined with risk features enhances outcomes. Test cost, performance, and predictive value affect cost-effectiveness. More data needed on ctDNA's role in treatment response prediction. Read more:

A meta-analysis of 86 studies on immunotherapy in NSCLC reveals: KRAS G12C & MET amplification show strong responses; EGFR, ALK, HER2, RET, ROS1 exhibit limited benefit from monotherapy; combination therapies significantly improve outcomes. Read more: buff.ly/oH9GKGz #Cancer #NSCLC #Immunotherapy

📊 Real-world data from Spain shows that nal-IRI + 5-FU/LV offers survival benefits for patients with advanced #PDAC, with outcomes comparable to clinical trials. Dive into the full TAMO study: buff.ly/hOvxr4Q #PancreaticCancer #RealWorldEvidence #TAMO #ESMO25 #OncologyResearch

As #ESMO25 wraps up, we celebrate the science - and the people behind it. Huge congratulations to TAM Associate Editor Dr. Natasha Leighl on receiving the Women for Oncology Award! A true leader in cancer care. 👏 #WomenInSTEM #OncologyLeadership

Following the buzz around #ESMO25? Dive deeper with our review article - a timely read as we explore the future of ADCs. 🔗https://buff.ly/ovkYahi #ADC #CancerTherapy #OncologyResearcH

🎉 #ESMO25 begins today! While I’m not attending in person, I’ll be following the talks closely from Shanghai. Looking forward to insights on #PrecisionOncology, #Immunotherapy, #ADCs and more. Let’s connect and share highlights! #OncologyCommunity #CancerResearch

@tamedoncol.bsky.social Navigating the Roadmap of New Treatment Options in HR+HER2- Advanced BC Despite major advances, metastatic HR+HER2- BC remains incurable. This Collection invites original research, reviews & meta-analyses Deadline: Dec 01, 2025 🔗 buff.ly/etMC9S7 #Oncology #BreastCancer

🎉 Honoring excellence in oncology! Huge congratulations to our Associate Editor Dr. Natasha Leighl on receiving the #ESMO25 Women for Oncology Award. A true leader in advancing cancer care and inspiring the next generation of researchers. #WomenInSTEM #OncologyLeadership #lungcancer

CDK4/6 inhibitors are making waves in early breast cancer care. This guide explores how abemaciclib & ribociclib are being integrated into adjuvant therapy for HR+, HER2− EBC - plus tips on managing side effects & improving adherence. Check it out: buff.ly/Lpmp3f0 #oncology #breastcancer #cdk46

🔍 PARP inhibitors in advanced prostate cancer @tamedoncol.bsky.social ✅ Effective in HRR-deficient mCRPC 🔗 Promising combos with ARSi, radiation, chemo & more 📘 Future directions explored Read the review 👉 buff.ly/FPovbjB #ProstateCancer #PARPi #Oncology

While monoimmunotherapy has limited impact in several subtypes, combination approaches show promise, especially in KRAS G12C, BRAF non-V600E, and MET-amplified cases. Precision matters. buff.ly/AyrHAkr #NSCLC #Immunotherapy #Oncology

🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:

Zolbetuximab is gaining attention as a targeted therapy for CLDN18.2-positive gastric and GEJ cancers. This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data. buff.ly/ok6eO7y #Oncology #GastricCancer #Zolbetuximab

🧬 Article collection on @tamedoncol.bsky.social: PARPi in Gynecologic Cancers. This collection highlights research on HRR genetic landscape, PARPi outcomes, oxaliplatin sequencing in BRCA-mutated ovarian cancer, and PARPi resistance with combination strategies. 📚 Explore more

Lung cancer is varying by region in risks and traits. A new article examines carcinogens, genetic predisposition, and molecular epidemiology. We seek submissions on geographic differences in lung cancer. Deadline: Dec 31, 2025 🔗 buff.ly/JCo9lJP #CancerResearch #LungCancer #GlobalHealth

🚨Call for Papers: @tamedoncol.bsky.social invites submissions on Antibody Drug Conjugates (ADCs) in Gynecologic Cancers. Led by Dr. Angélica Nogueira Rodrigues & Dr. Rowan Miller, this collection spotlights innovative ADC research in gynecologic oncology. 📥 Submit your work. buff.ly/RhdEIHX

🌟 Discover our top-cited article at @tamedoncol.bsky.social on aberrant DNA methylation in cancer. This review delves into epigenetic influences from BRCA1 to ctDNA, highlighting diagnostic, prognostic, and therapeutic impacts. 📖 Read more 🌟 buff.ly/ZAp0iD3

🧬 Just launched! The latest article collection from @tamedoncol.bsky.social dives into rare cancers with a clinical lens. 📚 Explore the collection

🌟 Most cited in its year! Explore Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4 in @tamedoncol.bsky.social. This review highlights promising multivariate assays like ROMA, OVA1 & Overa that could transform early OC detection. 📖 Read the article buff.ly/49NiTuO

Our article collection on Women in @tamedoncol.bsky.social is now live! Featuring powerful research led by women in oncology Check it out and celebrate women driving innovation in cancer care: journals.sagepub.com/topic/collec... #WomenInScience #Oncology #CancerResearch #BlueSkyScience

🌟 New Special Collection! 🌟 "Navigating New Treatment Options in HR+HER2- Advanced Breast Cancer" is now open for submissions. We invite researchers and clinicians to share their insights. 🔗 Submit journals.sagepub.com/topic/collec... Join us to improve patient care and outcomes. 🚀

I am thrilled to share that I have taken on the role of Editor for Thera Adv in Med Oncology @tamedoncol.bsky.social, succeeding my wonderful colleague, Georgia Patey. I am excited to collaborate closely with our editorial board members, authors, and readers. journals.sagepub.com/home/tam